|Awarded On||May 18, 2022|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Elizabeth Wasmuth|
|Summary of Goals and Objectives||
The androgen receptor (AR) is the master transcription factor responsible for development and maintenance of the male phenotype. Hyperactive AR signaling caused by AR gene amplification or coactivator overexpression is a hallmark of metastatic prostate cancer, which remains a major health burden in South Texas. Drugs that inhibit AR by outcompeting its steroid ligands have been used since the 1940s; however, resistance to these therapeutics inevitably arises through rebounds in AR signaling or alternative pathways that render tumors AR-independent. Development of more effective therapies that target AR’s oncogenic function requires a robust in vitro system that faithfully recapitulates AR ac...